CrystalGenomics Inc (083790) - Total Liabilities

Latest as of September 2025: ₩124.24 Billion KRW ≈ $84.20 Million USD

Based on the latest financial reports, CrystalGenomics Inc (083790) has total liabilities worth ₩124.24 Billion KRW (≈ $84.20 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CrystalGenomics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

CrystalGenomics Inc - Total Liabilities Trend (2011–2024)

This chart illustrates how CrystalGenomics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CrystalGenomics Inc balance sheet assets.

CrystalGenomics Inc Competitors by Total Liabilities

The table below lists competitors of CrystalGenomics Inc ranked by their total liabilities.

Company Country Total Liabilities
Etrend Hightech
TWO:3567
Taiwan NT$73.48 Million
Geomega Resources Inc
V:GMA
Canada CA$5.97 Million
FN REPUBLIC Co. Ltd
KQ:064090
Korea ₩3.75 Billion
C-Com Satellite Systems Inc.
V:CMI
Canada CA$2.54 Million
OSK Ventures International Bhd
KLSE:0053
Malaysia RM63.51 Million
Apollo Power Ltd
TA:APLP
Israel ILA91.02 Million
Intergama
TA:INTR
Israel ILA26.66 Million
SONOKONG Co. Ltd
KQ:066910
Korea ₩60.56 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down CrystalGenomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 083790 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.45 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.82 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.59 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CrystalGenomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CrystalGenomics Inc (2011–2024)

The table below shows the annual total liabilities of CrystalGenomics Inc from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩161.95 Billion
≈ $109.75 Million
+65.55%
2023-12-31 ₩97.82 Billion
≈ $66.29 Million
-27.18%
2022-12-31 ₩134.34 Billion
≈ $91.04 Million
+7.39%
2021-12-31 ₩125.09 Billion
≈ $84.77 Million
+22.39%
2020-12-31 ₩102.20 Billion
≈ $69.26 Million
-55.59%
2019-12-31 ₩230.14 Billion
≈ $155.96 Million
+217.64%
2018-12-31 ₩72.45 Billion
≈ $49.10 Million
+159.89%
2017-12-31 ₩27.88 Billion
≈ $18.89 Million
-38.74%
2016-12-31 ₩45.51 Billion
≈ $30.84 Million
-17.77%
2015-12-31 ₩55.34 Billion
≈ $37.51 Million
+8.47%
2014-12-31 ₩51.02 Billion
≈ $34.58 Million
-3.01%
2013-12-31 ₩52.61 Billion
≈ $35.65 Million
+62.91%
2012-12-31 ₩32.29 Billion
≈ $21.88 Million
-0.92%
2011-12-31 ₩32.59 Billion
≈ $22.09 Million
--

About CrystalGenomics Inc

KQ:083790 Korea Pharmaceuticals
Market Cap
$26.89 Million
₩39.68 Billion KRW
Market Cap Rank
#24215 Global
#1712 in Korea
Share Price
₩981.00
Change (1 day)
+1.87%
52-Week Range
₩744.00 - ₩1768.00
All Time High
₩18365.04
About

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more